Research Article

Evaluating the Toxicity and Histological Effects of Al₂O₃ Nanoparticles on Bone Tissue in Animal Model: A Case-Control Study

Hossein Soltaninejad, Hadi Zare-Zardini, Amir Ali Hamidieh, Mohammad Reza Sobhan, Seyed Houssein Saeed-Banadaky, Mohammad Amir Amirkhani, Behnaz Tolueinia, Mohsen Mehregan, Mahnaz Mirakhor, and Farzaneh Sadat Eshaghi

1Department of Nano Biotechnology, Faculty of Biological Sciences, Tarbiat Modares University, Tehran 14115, Iran
2Iranian Tissue Bank & Research Center, Tehran University of Medical Sciences, Tehran, Iran
3Hematology and Oncology Research Center, Shahid Sadoughi University of Medical Sciences, Yazd, Iran
4Medical Nanotechnology & Tissue Engineering Research Center, Yazd Reproductive Sciences Institute, Shahid Sadoughi University of Medical Sciences, Yazd, Iran
5Department of Sciences, Farhangian University, Isfahan, Iran
6Pediatric Cell Therapy Research Center, Tehran University of Medical Sciences, Tehran, Iran
7Department of Orthopedics, Shahid Sadoughi University of Medical Sciences, Yazd, Iran
8Stem Cell and Regenerative Medicine Institute, Tehran University of Medical Sciences, Tehran, Iran
9University of Applied Science and Technology of Sistan and Baluchestan, Minushargh Branch, Zahedan, Iran
10Department of Physics, Payam-e-noor University, Zahedan, Iran
11Shahid Sadoughi Hospital, Shahid Sadoughi University of Medical Sciences, Yazd, Iran
12Department of Genetics, Faculty of Medicine, Shahid Sadoughi University of Medical Sciences, Yazd, Iran

Correspondence should be addressed to Hadi Zare-Zardini; hadizarezardini@gmail.com

Received 15 May 2020; Revised 13 October 2020; Accepted 15 November 2020; Published 24 November 2020

Academic Editor: Mohamed M. Abdel-Daim

Copyright © 2020 Hossein Soltaninejad et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

The applications of nanostructures have been limited by their different toxicities. So, the investigation of these toxicities is necessary before nanostructure application. This study aimed to evaluate the effect of aluminum oxide (Al₂O₃) nanoparticles on bone density in Wistar rat. Al₂O₃ nanoparticle was prepared by the sol-gel method. Characterization was done by X-ray diffraction (XRD) and transmission electron microscopy (TEM). Sixty-four male adult Wistar rats were divided into eight groups including six groups intravenously treated with Al₂O₃ nanoparticle at concentrations of 25, 50, 100, 250, 500, and 1000 µg/ml: one group received food and water as the control group, and one group received food and water as well as intravenously distilled water as an injection control group. After 41 days, bone density was analyzed by dual-energy X-ray absorptiometry (DEXA). According to X-ray diffraction, the average particle size for Al₂O₃ nanoparticles was 20.85 nm. The data of densitometry showed that the bone density of right and left foot was reduced in concentrations of 250, 500, and 1000 µg/ml that were statistically significant in comparison with the control group. The reduction of bone density was increased with the enhancement of nanostructures concentration. The effect of Al₂O₃ nanoparticles on bone density was similar in the left and right legs. Histopathological assessment also showed that Al₂O₃ nanoparticles (250, 500, and 1000 µg/ml) lead to significant reduction of trabeculae. Empty lacunae are observed in these three groups. Considering that high concentrations of Al₂O₃ nanoparticles had toxicity on bone tissue, it must be used by more caution, especially its use as a coating in different devices such as implants, surgical instruments, and bone prostheses.
1. Introduction

Recently, nanostructures have found increased applications in technology, research, and medicine [1–3]. These compounds have unique properties because of their small size. In the past decades, the use of nanotechnology has risen in science due to their wide range of biomedical applications, for example, in antimicrobial agents [3], coating [4], drug delivery [5, 6], medical imaging [7], the optoelectronic device [8], suitable catalyst [9], and other beneficial applications [10–15]. Besides beneficial properties, nanostructures have dangerous toxicity on all of the worlds, especially on human life [16, 17]. For some types of particles, the smaller size leads to a greater surface area/volume ratio and higher chemical reactivity and biological activity [18, 19]. The toxicity of different nanostructures has been proven on different organs such as blood, lungs, liver, skin, gut, heart, reproductive organ, and other organs [20]. Once in the bloodstream, nanostructures can be transported around the body and be taken up by organs and tissues, including the brain, heart, liver, kidneys, spleen, bone marrow, and nervous system [21]. Nanomaterials are toxic for human tissue and cell cultures, resulting in increased oxidative stress, inflammatory cytokine production, and cell death. Nanostructures may be taken up by cell mitochondria and the cell nucleus. Nanomaterials can cause DNA mutation and induce major structural damage to mitochondria. The one organ that effects of nanostructures is bone. Nanostructures can penetrate deeper into skin layers and possibly be absorbed into the systemic circulation and accumulate in tissues, especially in bone because of the development of nanodevices that are used in surgical instruments and bone prostheses. So, the evaluation of the toxicity of nanostructures on bone is a very important field of nanotoxicology. Alumina is one of the inert biomaterials used in implants [22, 23]. It is, therefore, a biodegradable material, well-tolerated by the biological environment. This nanostructure has been defined as a suitable compound that is used in different fields of life. Thus, the present paper aims to investigate the toxic effect of Al2O3 on the bone.

2. Materials and Methods

2.1. Materials. Aluminum chloride (AlCl3) and ethanol were purchased from Sigma. Other used chemicals were analytical grade.

2.1.1. Synthesis and Characterizations of Nanostructures. According to our previous study [24] and other related articles [25–27], the sol-gel method was used for the synthesis of nanostructures. In brief, AlCl3 ethanolic solution (0.1 M) was prepared. NH3 solution (28%) was added to AlCl3 ethanolic solution. In this stage, a gel was formed. This acquired gel was incubated at room temperature for 30 hours. Then, the acquired agent was dried at 100°C for 24 hours.

X-ray diffraction (XRD) and transmission electron microscope (TEM) were used for identifying the crystalline mineralogical phases of the powders and micrographs, respectively.

The size of nanocrystals has been calculated using the Debye–Scherrer formula using reflection from the XRD pattern. Debye–Scherrer formula for crystallite size determination is given as follows:

\[
D = \frac{0.94\lambda}{\beta \cos \theta}
\]

where, \(D\) is the crystallite size, \(\lambda\) is the wavelength of X-ray, \(\beta\) is the full width at half maximum, and \(\theta\) is Bragg’s angle.

2.1.2. Investigation of Bone Density. For investigating the effect of Al2O3 nanoparticles on bone density, 64 male adult Wistar rats (mean body weight = 245 g) were used. All ethics were well-considered standards in compliance with the Animal Welfare Act. The research was approved by the ethics committee of Shahid Sadoughi University of Medical Sciences. The Wistar rats were kept in metal cages with standard conditions (environment temperature: 25°C, suitable humidity: 50%, and sufficient light: 12/12 hours light/dark). A proper diet consisting of fats, carbohydrates, protein, and vitamins was given. Rats were randomly divided into 8 groups (8 rats in each group) which are as follows:

- The control group (group 1): regular foods
- Injection control (group 2): intravenous injection of 0.5 ml distilled water alongside regular food
- Six treatment groups: intravenous injection of 0.5 ml Al2O3 nanoparticles in different concentrations alongside regular food as group 3 (25 µg/ml), group 4 (50 µg/ml), group 5 (100 µg/ml), group 6 (250 µg/ml), group 7 (500 µg/ml), and group 8 (1000 µg/ml)

Following the treatment of eight Wistar rats in each group during 40 days, dual-energy X-ray absorptiometry (DEXA) was used for bone densitometry. In brief, in this method, two sources of the X-ray were irradiated to bone. In a higher density of bone, the X-ray absorption was greater. This condition leads to less radiation reaching the detector. The radiation received to the detector was calculated and converted to the scale of bone density as g/cm² by computer analysis.

2.1.3. Histological Examination. For histological evaluation, bone samples (control group and group 8) were prepared and fixed in paraformaldehyde. After 24 hours, samples were dehydrated by ethanol and embedded in paraffin. Thin slices were prepared by block cutting. Staining was done with hematoxylin and eosin (H&E) solution. Qualitative assessment was done by a pathologist under a light microscope based on experiences and references.
2.1.4. Statistical Analysis. The data were analyzed by SPSS (version 20). Means ± SD were calculated for the average bone density. These calculated data were compared between groups by one-way analysis of variance (ANOVA) followed by Tukey’s test as post hoc. A p value of less than 0.05 was considered significant.

3. Results

3.1. Synthesis and Characterizations of Nanostructure. 

Al₂O₃ nanoparticles were synthesized by the sol-gel method and characterized by X-ray diffraction and scanning electron microscopy (TEM). Figure 1 shows the XRD pattern of alumina powder. The particle size of Al₂O₃ nanoparticles was 20.85 nm. Figure 2 shows the transmission electron microscopy (TEM) micrographs of alumina powder obtained from aluminum chloride solution (0.1 M), heat-treated at 100°C for 24 hours. There are two types of particles with different geometries, namely, needle-shaped particles with an average particle size below 30 nm and spherical particles with an average size below 20 nm. This figure also showed the SEM micrographs of synthesized nanostructures and proper synthetic processes.

3.2. Bone Evaluation. 

Bone densitometry was done on both left and right feet. Being treated with different concentrations of Al₂O₃ nanoparticle led to change in the bone density in all treated groups. Investigating the mean of bone density in different groups showed the highest density at the lowest concentration of nanostructure (25 µg/ml, 0.1498 ± 0.001 and 0.1485 ± 0.002 g/cm² for left and right foot, respectively) and the lowest bone density at the highest concentration (1000 µg/ml, 0.1012 ± 0.002 and 0.098 ± 0.003 g/cm² for left and right foot, respectively) (Table 1). Based on the ANOVA test, the differences between some of the means are statistically significant. The results of Tukey’s test showed that the change of bone density in groups treated with concentrations of 250, 500, and 1000 µg/ml of Al₂O₃ nanoparticle had a significant reduction compared to the control group (p < 0.05). The observed reductions in the treatment group treated at the concentration of 25, 50, and 100 µg/ml were not significant compared to the control group (p > 0.05). These changes were observed in both feet. Histopathological assessment showed that 1000 µg/ml of Al₂O₃ nanoparticles led to significant reduction of trabeculae. Empty lacunae are observed in this group. In treated groups with 500 µg/ml, empty lacunae and reduction of trabeculae are also observed. In treated groups with 250 µg/ml, the side effect of nanoparticle is less than treated groups with 500 and 1000 µg/ml. However, reduction of trabeculae was also observed in this group, to some extent. The bone matrix is reduced in treated groups with 250, 500, and 1000 µg/ml of nanoparticle, and osteocyte cell destruction is evident. The rate of destruction of the bone matrix and blades is higher in treated groups with 1000 µg/ml than other groups. In control group, intact and dense bone with complete trabecular structure was observed. The similar condition was observed in the injection control group and treated groups with 25, 50, and 100 µg/ml of Al₂O₃ nanoparticles. The overall appearance of the bones in control group, injection control group, and treated groups with 25, 50 and 100 µg/ml of Al₂O₃ nanoparticles was normal. A healthy bone matrix with cylindrical osteocyte and lacunar around it is clear in these groups (Figure 3).

4. Discussion

Nanomaterials show toxicological properties in comparison with the same substance in the bulk form [28]. The use and release of nanostructures into the environment can affect each stage of a life cycle [29]. The knowledge about the toxicity of nanomaterials is incomprehensive, especially long-term environmental and chronic health impacts [30]. These nanomaterials can lead to a defect in all organs of the body such as liver, blood, brain, lung, and, even, bone tissue [31–34]. In this study, the effect of Al₂O₃ nanoparticles on bone density was investigated by DEXA method in Wistar rats. In X-ray analysis of synthesized Al₂O₃ nanoparticles, Shimadzu diffractometer XRD 6000-Ni-filtered CuKα (λ = 1.5406 Å) radiation, scanning speed of 0.02°/min, in 2θ = 10–70 deg. range was used [24]. Based on this analysis, the particle size of Al₂O₃ nanoparticles was 20.85 nm. Based on these results and similar studies [35, 36], we synthesized relatively highly pure nanostructures without any unwanted impurities. In TEM graph, needle- and sphere-shaped nanoparticles were seen. Similar to XRD data, the mean size of synthesized Al₂O₃ nanoparticles was below 30 nm. In TEM graph, agglomeration of Al₂O₃ nanoparticles was also seen. SEM analysis was confirmed in TEM and XRD data. Surface charge is one of the important reasons for the stability of colloidal particles, especially metal oxide nanoparticles. The surface charge of nanoparticles is pH-dependent and raises the intrinsic properties of the oxides on their surface. Observed agglomeration could be due to this fact [25, 26, 36]. The results showed that the treatment of Wistar rats with different concentrations of Al₂O₃ nanoparticles led to changes in bone tissue. This treatment leads to a reduction of bone density of both feet in all used concentrations. But this reduction was statistically significant in a concentration higher than 250 µg/ml. According to these data, it seems that, in a high concentration of Al₂O₃ nanoparticles, reduction of bone density is possible. Thus, Al₂O₃ nanoparticles have an important role in the change of bone density. Al₂O₃ nanoparticles can lead to bone osteoporosis. According to the literature review, no article studies investigated the effect of Al₂O₃ nanoparticles on bone density. So, the novelty of this study is that it evaluates the toxicity of Al₂O₃ nanoparticles on bone tissue. Other reports have proven the toxicity of different nanostructures on the different organisms (humans, plants, and different other animals) as well as different organs of animals (heart, liver, lung, blood, and brain) [16, 17, 37]. In these reports, it is proven that nanostructures can inhibit, reduce, and defect the activity of organs and so lead to cell death. This study proved that the toxicity of nanostructures on bone tissue could be possible. The behaviors of nanostructures are not similar to normal materials so that these nanostructures can...
be toxic to cells, tissues, and organs. Agglomeration and aggregation of nanoparticles can change these toxicities. As a result of their size and special properties, nanoparticles sometimes do not behave in the way that normal materials would, and it seems that HA particles can be slightly toxic to cells in the body if they start to clump together, or aggregate. Nanoparticles have higher toxicity at lower concentrations and shorter times in comparison with micro-/macroparticles [38, 39]. Our results showed similar toxicity for Al2O3 nanoparticles in bone density. Similar to our study, Korani et al. showed that different concentrations of silver nanoparticles had bone toxicities. This group showed that abnormal inflammatory responses and reduction of bone density occurred in nanotreated groups [40]. Based on similar articles, aluminum can accumulate in the bone. This accumulation leads to the occupation of unmineralized type I collagen, destruction of calcification, and resulting in reduction of bone density. Aluminum can impair parathyroid hormone by accumulation in parathyroid glands. Researchers indicated that aluminum displacement of calcium

**Figure 1:** The XRD pattern of alumina powder obtained by sol-gel method from aluminum chloride (AlCl3), dried 100°C/24 h.

**Figure 2:** SEM (a) and TEM (b) images of alumina powder obtained by sol-gel method.

**Table 1:** Comparison of mean of bone density (g/cm²) among all groups (ANOVA test) and control and other groups (Tukey’s test).

| Groups | Mean ± SD (g/cm²) Left foot | p value | Mean ± SD (g/cm²) Right foot | p value |
|--------|-----------------------------|---------|-----------------------------|---------|
| 1      | 0.1521 ± 0.002              |         | 0.1489 ± 0.003              |         |
| 2      | 0.1554 ± 0.003              | 0.988   | 0.1510 ± 0.003              | 0.995   |
| 3      | 0.1498 ± 0.001              | 0.996   | 0.1485 ± 0.002              | 0.968   |
| 4      | 0.1387 ± 0.002              | 0.651   | 0.1396 ± 0.002              | 0.689   |
| 5      | 0.1388 ± 0.003              | 0.668   | 0.1389 ± 0.002              | 0.684   |
| 6      | 0.1221 ± 0.001              | 0.048*  | 0.1232 ± 0.001              | 0.046*  |
| 7      | 0.1159 ± 0.002              | 0.032*  | 0.1029 ± 0.001              | 0.016*  |
| 8      | 0.1012 ± 0.002              | 0.021*  | 0.098 ± 0.003               | 0.009*  |

*p value 0.036 0.024

Group definition: 1, control; 2, injection control; 3, treated with 0.5 ml Al2O3 nanoparticles (25 µg/ml); 4, treated with 0.5 ml Al2O3 nanoparticles (50 µg/ml); 5, treated with 0.5 ml Al2O3 nanoparticles (100 µg/ml); 6, treated with 0.5 ml Al2O3 nanoparticles (250 µg/ml); 7, treated with 0.5 ml Al2O3 nanoparticles (500 µg/ml); and 8, treated with 0.5 ml Al2O3 nanoparticles (1000 µg/ml).
Figure 3: Continued.
on the bone leads to bone complications such as osteomalacia, hypercalcemia, and hypercalciuria [41–46]. The above suggested mechanisms can be true in the mode of aluminum nanodimensions such as Al2O3 nanoparticles.

5. Conclusion

Based on this study, Al2O3 nanoparticles can reduce bone density. These results showed the toxicity of these nanostructures on bone tissue. So, due to the increasing use of nanostructures such as Al2O3 nanoparticles, it must be used by more caution, especially its use as a coating in different devices such as implants, surgical instruments, and bone prostheses.

Data Availability

The data used to support the findings of this study are included within the article.

Conflicts of Interest

The authors declare that they have no conflicts of interest.

References

[1] J. Jeevanandam, A. Barhoum, Y. S. Chan, A. Dufresne, and M. K. Danquah, “Review on nanoparticles and nanostructured materials: history, sources, toxicity and regulations,” Beilstein Journal of Nanotechnology, vol. 9, pp. 1050–1074, 2018.

[2] H. Zare-Zardini, A. Alemi, A. Taheri-Kafhari, et al., “Assessment of a new ginsenoside Rh2 nanoniosomal formulation for enhanced antitumor efficacy on prostate cancer: an in vitro study,” Drug Design, Development and Therapy, vol. 14, pp. 3315–3324, 2020.

[3] H. Zare-Zardini and M. Shanbedi, H. Soltaninejad et al., The effect of temperature and acidity on antimicrobial activities of pristine MWCNTs and MWCNTs-arg,” International Journal of Nanoscience and Nanotechnology, vol. 16, no. 2, pp. 127–136, 2020.

[4] A. Grumezescu, Surface Chemistry of Nanobiomaterials: Applications of Nanobiomaterials, William Andrew, Amsterdam, Netherlands, 2016.

[5] I. Tsuji, J. Kojima, and P. J. Fitzgerald, “Drug delivery via nano-, micro and macroporous coronary stent surfaces,” Expert Opinion on Drug Delivery, vol. 4, no. 3, pp. 287–295, 2007.

[6] H. Zare-Zardini, A. Taheri-Kafhari, M. Ordooei, A. Amiri, and M. Karimi-Zarchi, “Evaluation of toxicity of functionalized graphene oxide with ginsenoside Rh2, lysine and arginine on blood cancer cells (K562), red blood cells, blood coagulation and cardiovascular tissue: in vitro and in vivo studies,” Journal of the Taiwan Institute of Chemical Engineers, vol. 93, pp. 70–78, 2018.

[7] H. Zare-Zardini, F. Fardowsian, H. Soltaninejad et al., “Application of nanotechnology in biomedicine: a major focus on cancer therapy,” in Journal of Nano Research, vol. 35, Trans Tech Publ, 2016.

[8] M. M. Stylianakis, “Optoelectronic Nanodevices,” Nanomaterials, vol. 10, no. 3, p. 520, 2020.

[9] H. K. Thabet, A. F. Al-Hossainy, and M. Imran, “Synthesis, characterization, and DFT modeling of novel organic compound thin films derived from 2-amino-4-(2-hydroxy-3-methoxyphenyl)-4H-thiazolo[3,2-a][1,3,5]triazin-6(7H)-one,” Optical Materials, vol. 105, p. 109915, 2020.

[10] V. Latyshev, G. Krall, I. Alexandrov, and A. Fodor, “Application of bulk nanostructured materials in medicine,” Current Applied Physics, vol. 6, no. 2, pp. 262–266, 2006.

[11] S. Boncel, A. P. Herman, and K. Z. Walczak, “Magnetic carbon nanostructures in medicine,” Journal of Materials Chemistry, vol. 22, no. 1, pp. 31–37, 2012.

[12] J. He, X. Qi, Y. Miao, H.-L Wu, N. He, and J.-J. Zhu, “Application of smart nanostructures in medicine,” Nanomedicine, vol. 5, no. 7, pp. 1129–1138, 2010.

[13] A. Amiri, H. Z. Zardini, M. Shanbedi, M. Maghbere, M. Banadad, and B. Tolueinia, “Efficient method for
functionalization of carbon nanotubes by lysine and improved antimicrobial activity and water-dispersion,” Materials Letters, vol. 72, pp. 153–156, 2012.

[14] H. Z. Zardini, M. Davarpanah, M. Shanbedi, A. Amiri, M. Maghrebi, and L. Ebrahimi, “Microbial toxicity of ethanolamines-Multiwalled carbon nanotubes,” Journal of Biomedical Materials Research Part A, vol. 102, no. 6, pp. 1774–1781, 2014.

[15] H. Z. Zardini, A. Amiri, M. Shanbedi, M. Maghrebi, and M. Baniamad, “Enhanced antibacterial activity of amino acids-functionalized multi walled carbon nanotubes by a simple method,” Colloids and Surfaces B: Biointerfaces, vol. 92, pp. 196–202, 2012.

[16] H. Zare-Zardini, A. Amiri, M. Shanbedi et al., “In vitro and in vivo study of hazardous effects of Ag nanoparticles and arginine-treated multi walled carbon nanotubes on blood cells: application in hemodialysis membranes,” Journal of Biomedical Materials Research Part A, vol. 103, no. 9, pp. 2959–2965, 2015.

[17] H. Zare-Zardini, A. Amiri, M. Shanbedi et al., “Nanotechnology and pediatric cancer: prevention, diagnosis and treatment,” Iranian Journal of Pediatric Hematology and Oncology, vol. 5, no. 4, pp. 233–248, 2015.

[18] D. L. Leslie-Pelecky and R. D. Rieke, “Magnetic properties of nanostructured materials,” Chemistry of Materials, vol. 8, no. 8, pp. 1770–1783, 1996.

[19] H. Hahn, “Unique features and properties of nanostructured materials,” Advanced Engineering Materials, vol. 5, no. 5, pp. 277–284, 2003.

[20] A. S. Faqi, D. Richards, J. W. Hauswirth, and R. Schroeder, “Maternal and developmental toxicity study of sodium azide in rats,” Regulatory Toxicology and Pharmacology, vol. 52, no. 2, pp. 158–162, 2008.

[21] J. M. Tseng, C. Y. Kuo, M. Y. Liu, and C. M. Shu, “Emergency response plan for boiler explosion with toxic chemical releases at Nan-Kung industrial park in central Taiwan,” Process Safety and Environmental Protection, vol. 86, no. 6, pp. 415–420, 2008.

[22] A. F. El’Sadany, G. E. Masoud, M. S. Kamel, and A. M. Korsel, “Fracture resistance of all ceramic crowns supported by zirconia and alumina versus titanium implant abutments,” Tanta Dental Journal, vol. 10, no. 3, pp. 103–111, 2013.

[23] S. Affatato, P. Taddei, S. Carmignato, E. Modena, and A. Toni, “Severe damage of alumina-on-alumina hip implants: wear assessments at a microscopic level,” Journal of the European Ceramic Society, vol. 32, no. 14, pp. 3647–3657, 2012.

[24] M. Mehregan, H. Soltaniejad, B. Tolouei-Nia, H. Zare-Zardini, M. Zare-Shehneh, and L. Ebrahimi, “Al2O3 nanoparticles, a suitable compound for active control of biofouling,” in Nano of Nano Research, vol. 32, pp. 71–80, Trans Tech Publ., 2015.

[25] M. H. Abdel-Aziz, M. S. Zoromba, M. Bassyouni, M. Zwawi, A. A. Alshehri, and A. F. Al-Hossainy, “Synthesis and characterization of Co-Al mixed oxide nanoparticles via thermal decomposition route of layered double hydroxide,” Journal of Molecular Structure, vol. 1206, p. 127679, 2020.

[26] A. A. I. Abd-Elmageed, S. M. Ibrahim, A. Bourgezui, and A. F. Al-Hossainy, “Synthesis, DFT studies, fabrication, and optical characterization of the [ZnMC(TP)polymer (organic/inorganic) as an optoelectronic device,” New Journal of Chemistry, vol. 44, no. 20, pp. 8621–8637, 2020.

[27] A. F. Al-Hossainy, M. Bassyouni, and M. S. Zoromba, “Elucidation of electrical and optical parameters of poly(o-anthrancilic acid)-poly(o-amino phenol)/copper oxide nanocomposites thin films,” Journal of Inorganic and Organometallic Polymers and Materials, vol. 28, no. 6, pp. 2572–2583, 2018.

[28] M. Zhang, J. Jin, Y.-N. Chang, X. Chang, and G. Xing, “Toxicological properties of nanomaterials,” Journal of Nanoscience and Nanotechnology, vol. 14, no. 1, pp. 717–729, 2014.

[29] M. Palombo, M. Deshmukh, D. Myers, J. Gao, Z. Szekely, and P. J. Sinko, “Pharmaceutical and toxicological properties of engineered nanomaterials for drug delivery,” Annual Review of Pharmacology and Toxicology, vol. 54, no. 1, pp. 581–598, 2014.

[30] S. Sharii, S. Behzadi, S. Laurent, M. Laird Forrest, P. Stroeve, and M. Mahmoudi, “Toxicity of nanomaterials,” Chemical Society Reviews, vol. 41, no. 6, pp. 2323–2343, 2012.

[31] A. Kermanizadeh, D. Balharry, H. Wallin, S. Loft, and P. Møller, “Nanomaterial translocation-the biokinetics, tissue accumulation, toxicity and fate of materials in secondary organs-a review,” Critical Reviews in Toxicology, vol. 45, no. 10, pp. 837–872, 2015.

[32] A. Kumar, P. Kumar, A. Anandan, T. F. Fernandes, G. A. Ayoko, and G. Biskos, “Engineered nanomaterials: knowledge gaps in fate, exposure, toxicity, and future directions,” Journal of Nanomaterials, vol. 2014, p. 16, Article ID 130198, 2014.

[33] J. Zhao and V. Castranova, “Toxicology of nanomaterials used in nanomedicine,” Journal of Toxicology and Environmental Health, Part B, vol. 14, no. 8, pp. 593–632, 2011.

[34] S. Soleymani, H. Zare Zardini, A. Ghorani azam et al., “A review of toxicity of some conventional nanomaterials,” Journal of Pharmaceutical & Health Sciences, vol. 2, no. 2, pp. 109–114, 2014.

[35] A. F. Al-Hossainy, M. S. Zoromba, M. H. Abdel-Aziz et al., “Fabrication of heterojunction diode using doped-poly-(ortho-aminophenol) for solar cells applications,” Physica B: Condensed Matter, vol. 566, pp. 6–16, 2019.

[36] A. F. Al-Hossainy, M. R. Eid, and M. S. Zoromba, “Structural, DFT, optical dispersion characteristics of novel [DPPA-Zn(MR(Cl)(H2O)) nanostructured thin films,” Materials Chemistry and Physics, vol. 232, pp. 180–192, 2019.

[37] S. Bakand, A. Hayes, and F. Dechsakulthorn, “Nanoparticles: a review of particle toxicity following inhalation exposure,” Inhalation Toxicology, vol. 24, no. 2, pp. 125–135, 2012.

[38] T. Gong, J. Xie, J. Liao, T. Zhang, S. Lin, and Y. Lin, “Nanomaterials and bone regeneration,” Bone Research, vol. 3, no. 1, p. 15029, 2015.

[39] Q. Wang, I. Yan, J. Yang, and B. Li, “Nanomaterials promise better bone repair,” Materials Today, vol. 19, no. 8, pp. 451–463, 2016.

[40] M. Korani, S. M. Rezayat, and S. Arbabzadeh, “Sub-chronic dermal toxicity of silver nanoparticles in Guinea pig: special emphasis to heart, bone and kidney toxicities,” Islamic Journal of Pharmaceutical Research: IJPR, vol. 12, no. 3, pp. 511–519, 2013.

[41] M. González-Suárez, M. Naves, C. Díaz-Corte, J. L. Fernández-Martín, P. Menéndez-Rodriguez, and J. B. Cannata-Andia, “Effect of aluminium on calcium-sensing receptor expression, proliferation, and apoptosis of parathyroid glands from rats with chronic renal failure,” Kidney International, vol. 63, pp. S39–S43, 2003.

[42] G. Klein, “Aluminum as a factor in the bone disease of total parenteral nutrition,” Transactions of the Association of American Physicians, vol. 95, pp. 155–164, 1982.
[43] G. L. Klein, A. C. Alfrey, N. L. Miller et al., “Aluminum loading during total parenteral nutrition,” The American Journal of Clinical Nutrition, vol. 35, no. 6, pp. 1425–1429, 1982.

[44] G. L. Klein, “Aluminum toxicity to bone: a multisystem effect?” Osteoporosis and Sarcopenia, vol. 5, no. 1, pp. 2–5, 2019.

[45] J. Morrissey, M. Rothstein, G. Mayor, and E. Slatopolsky, “Suppression of parathyroid hormone secretion by aluminum,” Kidney International, vol. 23, no. 5, pp. 699–704, 1983.

[46] A. B. Sedman, G. L. Klein, R. J. Merritt et al., “Evidence of aluminum loading in infants receiving intravenous therapy,” New England Journal of Medicine, vol. 312, no. 21, pp. 1337–1343, 1985.